At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMRN Immuron Ltd
Pre-Market Trading 12-23 07:27:38 EST
1.96
-0.03
-1.75%
High2.02
Low1.86
Vol4.43K
Open1.97
D1 Closing2.00
Amplitude7.77%
Mkt Cap11.23M
Tradable Cap9.61M
Total Shares5.73M
T/O8.55K
T/O Rate0.09%
Tradable Shares4.90M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th
Immuron Announces Sales (Unaudited) Of Travelan A$1.5M, Up 13% Prior Quarter, An OTC Immune Supplement Targeting Pathogenic Bacteria And Toxins Produced In The Gastrointestinal Tract
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.